Can AI Predict Lung Cancer on Chest Computed Tomography?
At the 2023 NACLC, Florian Fintelman, MD, presented a recap of data on the use of artificial intelligence for lung cancer risk prediction on chest CT.
Read More
Dissemination (Meeting Coverage)
2023 NACLC: Grab Lunch Here Before You Leave
Forget the O’Hare food kiosks and grab lunch at one of these locations instead, all within easy walking distance from the Chicago Marriott Downtown Magnificent Mile
Read More
Dr. Jonathan Spicer, 2023 NACLC Closing Keynote Speaker
Don’t miss the 2023 NACLC closing keynote—Perioperative Therapy—to be given by Jonathan Spicer, MD, PhD, 11:15 a.m.-12:15 p.m., Sunday, December 3, 2023.
Read More
2023 NACLC Sunday Schedule
Make the most of your final day at the 2023 NACLC conference—use the program information below to plan your schedule:
Read More
Minorities Remain Underrepresented in DME Clinical Trials
Many barriers exist in the recruitment for diabetic macular edema clinical trials of patients of minority racial and ethnic backgrounds.
Read More
PIRA Represents Most Common Form of Disability Accrual in Relapsing-Remitting MS
Key risk factors for progression independent of relapse activity in relapsing-remitting MS include age and longer disease duration.
Read More
Q&A: Examining Emerging Therapies to Restore Function in CNS Diseases in MS
More targeted, higher efficacious medications can drastically reduce the risk for accruing disability in newly diagnosed patients with MS.
Read More
Explore the Magnificent Mile While Attending 2023 NACLC
2023 NACLC is taking place in Chicago’s famous “Magnificent Mile” district, so be sure to set aside a little time for exploring!
Read More
2023 NACLC Satellite CME Symposia Cover an Array of Topics
Check out the fascinating array of topics to be covered during 2023 NACLC satellite CME symposia!
Read More
2023 NACLC Program
The IASLC 2023 North America Conference on Lung Cancer (NACLC) runs December 1-3, 2023, at the...
Read More
In Primary Progressive MS, Age & Follow-Up Duration Predict Disease Activity
For patients with primary progressive MS, age is a particularly important factor that predicts disease activity.
Read More
From Agent to Agent, Interleukin Inhibitors Offer Distinct Benefits in Psoriasis
The benefits of interleukin inhibitors vary by agent and include increased drug survival and earlier attainment of Psoriasis Area Severity Index scores.
Read More
Aflibercept 8 Mg Improves Visual Acuity in Diabetic Macular Edema
Aflibercept 8 mg shows efficacy for patients with diabetic macular edema regardless of sex, age, and race/ethnicity.
Read More
The Importance of Detecting Early NSCLC
Disease-free survival could be predicted by high expression of TGFβ CAF in patients with eNSCLC treated with atezolizumab.
Read More
Can Radiotracers Predict Response to PD-L1 Inhibitors in Early NSCLC?
Although immunotherapy advances have improved cancer treatments, there remains a need for reliable biomarkers.
Read More
Birdshot Chorioretinopathy Shows Fractal Changes in the Retinal Vascular Layers
Fractal dimensions represent a promising biomarker for assessing retinal vascular damage.
Read More
Treating Patients of Color With Psoriasis Presents Many Challenges
Dermatologists must be knowledgeable about differences among people of color with psoriasis and to tailor their approach to diagnosis and treatment accordingly.
Read More
Q&A: Sharing Knowledge Fosters a Better Understanding of MS
Progression independent of relapse activity explains why certain patients with MS continue to worsen clinically without MRI evidence of new lesions.
Read More
Q&A: Using Effective Treatments Earlier for NSCLC
“With lung cancer we’re treating more patients effectively today and even curing them because we’re using our most effective therapies earlier.”
Read More
Q&A: Availability of Multiple Options for NSCLC is “Very Exciting”
Selecting a treatment for operable non-small cell lung cancer from the many options available involves consideration of tumor stage and biomarkers.
Read More